Drug Profile


Alternative Names: DR4 mAB; HGS-1012; HGS-ETR1; TRAIL-R1 monoclonal antibody; TRM-1

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Human Genome Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cervical cancer
  • Suspended Liver cancer
  • No development reported Colorectal cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 10 Sep 2015 Phase-I/II development for Cervical cancer is ongoing in Netherlands
  • 10 Sep 2015 No recent reports on development identified - Phase-II for Multiple myeloma (Combination therapy) in USA, Canada, Australia and India (IV)
  • 10 Sep 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy) in USA, Germany, Hungary and Romania (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top